Provention Bio, Inc. Common Stock
PRVB
PRVB was delisted on the 26th of April, 2023.
132 hedge funds and large institutions have $477M invested in Provention Bio, Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 38 funds opening new positions, 57 increasing their positions, 16 reducing their positions, and 17 closing their positions.
329% more call options, than puts
Call options by funds: $19.4M | Put options by funds: $4.53M
256% more repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 16
155% more capital invested
Capital invested by funds: $187M → $477M (+$290M)
124% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 17
18% more funds holding
Funds holding: 112 → 132 (+20)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
+$8.38M |
| 2 |
6CM
683 Capital Management
New York
|
+$4.44M |
| 3 |
BlackRock
New York
|
+$4.43M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.35M |
| 5 |
Invesco
Atlanta,
Georgia
|
+$4.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$26.2M |
| 2 |
DCM
DG Capital Management
New York
|
-$2.25M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$1.54M |
| 4 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$889K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
-$691K |
PRVB Hedge Fund Activity: Q4 2022 in Review
132 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Provention Bio, Inc. Common Stock (PRVB) for Q4 2022, worth a combined $477M — up 155% from $187M a quarter earlier.
Buyers outnumbered sellers: 38 funds opened new PRVB positions and 17 closed out — a net gain of 21 holders — while 57 added to existing stakes and 16 trimmed.
The largest buyer was D.E. Shaw & Co, adding an estimated $8.38M. The largest seller was Adage Capital Partners, cutting an estimated $26.2M.
- 132 institutional investors held Provention Bio, Inc. Common Stock (PRVB) as of Q4 2022, up from 112 in Q3 2022.
- Funds reported $477M of Provention Bio, Inc. Common Stock stock for Q4 2022, up 155% quarter-over-quarter.
- 38 funds opened new Provention Bio, Inc. Common Stock positions in Q4 2022 and 17 closed out, a net change of +21 holders.
- The largest Provention Bio, Inc. Common Stock buyer in Q4 2022 was D.E. Shaw & Co, an estimated $8.38M added.
- The largest Provention Bio, Inc. Common Stock seller in Q4 2022 was Adage Capital Partners, an estimated $26.2M sold.
Based on aggregated 13F filings for Q4 2022.